INmune Bio, Inc. (INMB)
- GlobeNewswire
INmune Bio Inc. Presents Data on INB03’s Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024
Novel Immunotherapy Approach Targets Soluble Tumor Necrosis Factor to Overcome Resistance and Enhance Therapeutic Outcome in High-Risk Breast Cancer Boca Raton, Florida, April 08, 2024 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, is presenting data on the use of INB03, a dominant-negative tumor necrosis factor (TNF) inhibitor of soluble TN
- Insider Monkey
INmune Bio, Inc. (NASDAQ:INMB) Q4 2023 Earnings Call Transcript
INmune Bio, Inc. (NASDAQ:INMB) Q4 2023 Earnings Call Transcript March 28, 2024 INmune Bio, Inc. beats earnings expectations. Reported EPS is $-0.47, expectations were $-0.58. INMB isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Ladies and gentlemen, greetings and welcome […]
- Simply Wall St.
INmune Bio Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags
INmune Bio ( NASDAQ:INMB ) Full Year 2023 Results Key Financial Results Net loss: US$30.0m (loss widened by 9.9% from...
